lifestyle.marketresearchjournals.com

Author: Lunai Bioworks Inc.

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion

April 7, 2026
Lunai Bioworks Executes $20M Strategic Transaction at Fixed $1.50 Conversion, Acquiring BBB Delivery Platform for CNS Alzheimer’s Therapies with Broad CNS Delivery Applications

March 26, 2026
$400M to $1.2 Billion US Countermeasures Program Presents Huge Opportunity for New AI Platform to Meet Emerging Battlefield and Terrorism Threats: Lunai Bioworks (Nasdaq: LNAI)

March 23, 2026
Lunai Bioworks (NASDAQ: LNAI) Launches National Chemical Defense Consortium Targeting $400M-$1.2B U.S. Countermeasure Programs; 3-Year AI Antidote Development Model

March 19, 2026
Lunai Bioworks (NASDAQ: LNAI) Locks Down Core AI Architecture with U.S. Patent Enabling Precision Disease Subtyping

February 19, 2026
Lunai Bioworks (NASDAQ: LNAI) Highlights Drug Discovery and Biodefense AI Platform on CNBC

February 14, 2026
Lunai Bioworks (NASDAQ: LNAI) Launches AI Oncology Pilot with Clinical-Stage Partner to Analyze Randomized Phase 2 Metastatic Colorectal Cancer Survival Trial Data

February 12, 2026
Lunai Bioworks, Inc. Issues Letter to Shareholders

February 12, 2026
Lunai Bioworks (NASDAQ: LNAI) Launches Sentinel, an AI Safeguard to Block Large Language Models from Generating Novel Chemical Weapons

January 27, 2026
Lunai Bioworks (NASDAQ: LNAI) Expands NIH-Funded AI Program into Commercial Alcohol Use Disorder Drug Discovery

January 27, 2026